

Targeted Anticancer Therapies: Mouse Models Help Uncover the Mechanisms of Tumor Escape

Renée van Amerongen and Anton Berns*

*Correspondence: a.berns@nki.nl

DOI 10.1016/j.ccr.2008.02.012

(Cancer Cell 13, 5–7; January 2008)

We erroneously reported that the studies by [Williams et al. \(2006 and 2007\)](#) were performed in a mouse model for CML, which shows a favorable clinical response to imatinib treatment. In fact, their studies addressed the role of the p19ARF locus in BCR/ABL-driven ALL, which shows a poor response to treatment with imatinib. We sincerely apologize for this inaccuracy but feel compelled to inform the reader of our mistake.

REFERENCES

Williams, R.T., Roussel, M.F., and Sherr, C.J. (2006). Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. *Proc. Natl. Acad. Sci. USA* 103, 6688–6693.

Williams, R.T., den Besten, W., and Sherr, C.J. (2007). Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. *Genes Dev.* 21, 2283–2287.